Managing Excessive Bleeding
Excessive bleeding, as a result of trauma, surgery, bleeding disorders or other causes, is the most common preventable cause of death in modern society. RxMP Therapeutics is developing novel systemically-delivered hemostatic agents that are designed to arrest or prevent excessive bleeding, with the goal of improving healthcare outcomes while reducing costs and the need for transfused blood products.
About our technology
RxMP holds exclusive rights to technology for the manufacture and use of novel hemostatic agents based on red cell-derived microparticles. Such RMPs are found normally at low concentrations in the bloodstream, and clinical findings have shown that individuals at high risk of excessive bleeding who have high natural levels of RMPs are less likely than others to experience spontaneous bleeds.
